Introduction
Noninvasive imaging techniques are important clinical diagnostic tools in the investigation of gastrointestinal (GI) motility and transit. Several radiological and endoscopic techniques have been developed and are practised in clinical settings [1] . Among them, g scintigraphy is one of the most favoured diagnostic methods because it combines quantitative assessment and visual information from sequential image data. Furthermore, this methodology does not involve dense contrast agents such as barium, which may alter the GI physiology during the examination.
A range of nonabsorbable radiopharmaceuticals have previously been used for gastrointestinal studies [2] . In 1989, Camilleri et al. [3] from Mayo Clinic, USA, successfully developed a method of indium-111 (III) chloride ( 111 InCl 3 )-radiolabelled resin pellets for the assessment of gastric emptying and colonic transit. Amberlite IR-120 (H + ) cation resin pellets were successfully labelled with 111 InCl 3 , and this method has been widely practised in many centres, particularly for whole-gut transit studies [4] [5] [6] [7] . This method, however, has certain limitations restricting its application to a broader population, mainly because of the requirement of an industrial cyclotron facility for the production of 111 In, which is not commonly available worldwide. As a consequence, the supply of 111 In to some countries can be relatively costly compared with other available radionuclides, especially when this involves international shipment with the added cost of lead shielding and agent charges to comply with different national radiation authorities.
In 1998, Mullan et al. [8] suggested a cheaper approach for radiolabelling activated charcoal with technetium-99m pertechnetate and technetium-99m-diethylene triamine pentaacetic acid, which are routinely available in most countries. Some later publications [9] [10] [11] described the use of 99m Tc-radiolabelled ion-exchange resin pellets as an alternative for 111 In-radiolabelled resins; however, the short physical half-life of 99m Tc (6.02 h) makes this radiotracer formulation only suitable for short time-course imaging studies such as oesophageal transit or gastric emptying. The investigation of whole-gut transit requires a radiotracer with a much longer physical half-life, preferably around 24-72 h.
Samarium-153 (
153 Sm) has a physical half-life of 46.3 h and emits g radiation of 103 keV, which is well suited for g scintigraphic imaging [12] . Neutron-activated 153 Sm has successfully been used in various drug delivery and pharmacology studies [13] [14] [15] [16] . We have extensive experience with the production and use of 153 Sm as a tracer for studying the transit and release of oral dose forms such as enteric-coated matrix tablets [17, 18] 
ion-exchange resin was then added to the solution and mixed evenly. The mixture was dried in a laboratory oven for 12 h at a temperature of 701C. The dried resin beads were then filled into an empty gelatin capsule and sent for neutron activation.
Neutron activation
The samples were sent to the nuclear reactor facility at Malaysian Nuclear Agency, Bangi, Malaysia, for neutron activation. This facility is a 250 kW open pool-type research reactor (Triga Mark II, General Atomics, California, USA) that uses a uranium zirconium hydride assembly with low-enriched uranium-235 (20 wt% 235 U) for the fuel source. Before irradiation, each capsule was heat-sealed into a polyethylene vial. Three vials were packed into a polyethylene ampoule (commonly known as the 'rabbit'). The ampoule was delivered to the reactor core by a pneumatic transport system. The capsules were irradiated in a neutron flux of 1 Â 10 13 cm -2 s -1 for 100 s to achieve a nominal radioactivity of 5 MBq at 66 h after neutron activation. Gamma spectroscopy was carried out to detect any radioactive impurities 24 and 48 h after neutron activation using a coaxial, p-type, germanium detector (Canberra, Meriden, USA) and g spectrum analysis software (Genie 2000 Ver. 3.2, Canberra, Meriden, USA) . The safety requirement was that any net g peak area not originating from 153 Sm should not exceed 0.3% of the 153 Sm main peak at 103 keV and that the total net peak areas not originating from 153 Sm should not exceed 1% of the 153 Sm main peak. The capsules were kept in a radioactive storage room until the study day to allow for decay of the unwanted short-lived activated by-products, primarily sodium-24 ( 24 Na) [15, 16, 19] . 111 InCl 3 (molecular weight 221.18 g/mol, assay purity Z 99%) was purchased from General Electric Healthcare (The Grove Centre, Amersham, UK). A measure of 100 mg of Amberlite IR-120 (H + ) ion-exchange resin was weighed into a glass beaker. A volume of 5 MBq of 111 InCl 3 solution was prepared and added to the ionexchange resin. After mixing evenly using a glass rod, the radiolabelled compound was left to dry completely in a laboratory oven at a temperature of 701C.
Specific activities

Both
153 Sm-radiolabelled and 111 In-radiolabelled resins were weighed and assayed for radioactivity to derive the specific activity. Labelling efficiencies were obtained by determining the activity bound to the resin after washing for 5 min with distilled water. Retention of the radioactivity bound to resins over time was measured as described below.
Stability of radiolabelled resins in simulated gastric and intestinal fluid
The stability of the activated 153 Sm-resin and the 111 Inradiolabelled resin was measured in vitro over a period of 24 h. Artificial gastric juice (pH 1.03) and simulated intestinal fluid (pH 6.8) with enzyme incorporation were prepared according to the recommendation in the British Pharmacopoeia, 2007.
The activated 153 Sm-resins were emptied from the capsule and transferred to glass tubes containing either 10 ml of artificial gastric juice or 10 ml of simulated intestinal fluid. The initial activities of all the samples were measured using a dose calibrator (CRC-12, Capintec Inc., New Jersey, USA) and recorded. The tubes were then placed on a tilt and mix roller (Movil Rod, J.P. Selecta, Espano) and rolled constantly at 50 rpm for 1 h. The tubes were then transferred to a multipurpose centrifuge (CR4-12, Jouan Inc, St. Herblain, France) and rotated at 1200 rpm for 5 min to separate the resin beads and fluid. After centrifugation, 1 ml of fluid was carefully removed from the middle of the tube without disturbing the resin beads at the bottom using a micropipette. The same procedures of rolling and sampling were repeated every 2 h for 10 h, and a final sample was taken at 24 h. All the samples were then assayed using an automatic g counter (2470 Wizard   2 , PerkinElmer, Massachusetts, USA) for measurement of 153 Sm activity. The g counter was precalibrated using a standard 153 Sm source from a secondary standard dosimetry laboratory (SSDL, Malaysian Nuclear Agency, Bangi, Malaysia). Background counting was carried out, followed by sample counting.
The procedures explained above were repeated six times for both 153 Sm-radiolabelled and 111 In-radiolabelled formulation in both simulated gastric and intestinal fluid.
Data analysis
The g counting data were first corrected for background count rates before further analysis. The count rates collected from 1 ml samples were normalized according to the volume remaining in the test tube at the time of sampling. The data were then corrected for radioactive decay and expressed as a percentage to the initial activity. The retention of radioactivity was calculated using the following formula:
Initial activity of resin À activity of sample Initial activity of resin Â 100 %
Results
Production of 153 Sm-resin by neutron activation was successfully achieved on 18 separate occasions. Assay of individual batches by g spectroscopy showed that the main photopeaks measured were in the expected energy region of 69.0 ± 1.5 and 102.6 ± 1.5 keV, both were g energies emitted by activated 153 Sm. A further peak at 1020.3 ± 1.5 keV was measured. This decayed with a physical half-life of 14.9 h and was consistent with the decay of activated 24 Na. The only other significant peaks produced were of low energy, at 40.3 and 46.1 keV, which were observed to decay with the same physical half-life as the main 153 Sm peak.
The mean (n = 18) specific activity of activated 
Discussion
This study demonstrates the production and stability of 153 Sm-radiolabelled cation-exchange resin compared with the established method of radiolabelling resin with 111 In. Amberlite IR-120 (H + ) cation-exchange resin has been shown in this study to be a suitable insoluble polymer that can be bound to 152 Sm 3+ ions through ion-exchange reaction and activated to a radioactive tracer for scintigraphic imaging. Amberlite IR-120 (H + ) resin is a gel-type strongly acidic cation exchange resin of the sulphonated polystyrene type. The name 'Amberlite' was given because of its physical appearance of amber spherical beads. The chemical structure of the resin is shown in Fig. 2 . In this study, the latter approach was used mainly for the purpose of radiation safety. This had the advantage of eliminating the manipulation of 111 In liquid and drying of the resin during the radiolabelling procedure at the hospital site.
As the resin and gelatin capsules were also directly irradiated during neutron activation, it was necessary to consider contamination with other activated products, particularly within the resin itself. Gamma spectroscopy demonstrated that the main product was 153 Sm and, as expected, there was evidence of short-lived 24 Na. The other low-energy peaks at 40.3 and 46.1 keV were considered to be low energy scatter from the 153 Sm photopeak, which they decayed at the same physical half-life as 153 Sm.
For clinical use, the radiolabelled resin can be administered within the gelatin capsule, or it can be emptied from the capsule for incorporation into a suitable meal or oral formulation. Before clinical use it is important that the stability of the resins be tested in vitro over time in a simulated GI environment. A review of the literature found little data on the stability of the resin formulations commonly used for GI investigation. One of our main concerns was that the molecular structure of the resins might be altered by the acidic condition in the stomach, hence releasing free 153 In 3+ ions showed 100% retention at the first sampling (0 h) but released slowly and gradually from the resins from 0 -24 h.
When considering the radiation burden, the effective dose to subjects administered with 153 Sm is 0.7 mSv per MBq [20] which is over twice that from 111 In at 0.3 mSv per MBq [21] . For routine use, studies of whole-gut transit may be undertaken with the order of 5 MB 153 Sm, resulting in an effective dose of 3.5 mSv. This is considered acceptable, and, although this is a disadvantage of samarium-153, it is still low when compared with the use of X-ray procedures that may be used in countries where indium is not routinely available. Sm product is the cost of neutron activation. The cost of raw materials, i.e., nonradioactive 152 Sm and cation-exchange resin, are minimal, at about 0.50h per sample. Commercial neutron activation services at a European research reactor typically costs about 100h per sample, on the basis of our previous experience [18] . The cost for 153 Sm obtained from MNA in this study was similar. In comparison, the price of In-indium-111 chloride is approximately 350h per 37 MBq within the United Kingdom. This equates to approximately 50h for 5 MBq-administered activity per patient. However, the cost of transportation for international shipping of radioactivity would double the product price, depending on 
